Patent Application
20240009261
The present disclosure relates to a prebiotic composition and a method for weight loss by using the same. A black tea ferment and a bioactive substance are used for preparing the prebiotic composition, and the prebiotic composition is used for weight loss.
Prebiotics, also known as GOS/FOS, are generally polysaccharides that are not easily digested by human enzymes in natural foods. According to the joint statement of the International Scientific Association for Probiotics and Prebiotics (ISAPP) on “Nature report” on the prebiotics in 2017, prebiotics are defined as “a substance that can be selectively utilized by microorganisms which are symbiotic with a host so as to promote the health of the host”.
Probiotics in the digestive system (mainly the large intestines) can utilize prebiotics to grow, expand and metabolize in flora so as to generate short-chain fatty acids (SFCAs).
That is, the prebiotics can help the growth of probiotics and help to inhibit harmful bacteria in intestinal tracts. Probiotics in the intestinal tracts may also metabolize prebiotics to generate SCFAs, and then the SCFAs are provided for probiotics and the host as energy sources.
In view of this, the present disclosure provides a prebiotic composition. The prebiotic composition includes a black tea ferment and a bioactive substance, can promote the growth ability of Hafnia alvei in the intestinal tract of a subject, and is used for helping the subject to lose weight.
In some embodiments, the prebiotic composition includes the black tea ferment and the bioactive substance. The bioactive substance is soybean peptide powder, pea protein, rice protein, corn oligopeptide powder, or a combination thereof. The black tea ferment is prepared by the following steps: extracting tea leaves of Camellia sinensis with water at 50° C. to 100° C. for 0.5 hours to 3 hours to obtain a black tea extract, and fermenting the black tea extract with Saccharomyces cerevisiae BCRC20271, Bifidobacterium lactis BCRC910887, Lactobacillus gasseri BCRC910886, and Gluconacetobacter xylinus BCRC12335 for 12 days to 25 days to obtain the black tea ferment.
In some embodiments, use of a prebiotic composition in preparation of a composition for weight loss is provided. The prebiotic composition includes a black tea ferment and a bioactive substance. The bioactive substance is soybean peptide powder, pea protein, rice protein, corn oligopeptide powder, or a combination thereof. The black tea ferment is prepared by the following steps: extracting tea leaves of Camellia sinensis with water at 50° C. to 100° C. for 0.5 hours to 3 hours to obtain the black tea extract, and fermenting the black tea extract with Saccharomyces cerevisiae BCRC20271, Bifidobacterium lactis BCRC910887, Lactobacillus gasseri BCRC910886, and Gluconacetobacter xylinus BCRC12335 for 12 days to 25 days to obtain the black tea ferment.
In some embodiments, a method for weight loss of a subject in need includes: administering an effective dose of a prebiotic composition to the subject in need. The prebiotic composition includes a black tea ferment and a bioactive substance. The bioactive substance is soybean peptide powder, pea protein, rice protein, corn oligopeptide powder, or a combination thereof. The black tea ferment is prepared by the following steps: extracting tea leaves of Camellia sinensis with water at 50° C. to 100° C. for 0.5 hours to 3 hours to obtain the black tea extract, and fermenting the black tea extract with Saccharomyces cerevisiae BCRC20271, Bifidobacterium lactis BCRC910887, Lactobacillus gasseri BCRC910886, and Gluconacetobacter xylinus BCRC12335 for 12 days to 25 days to obtain the black tea ferment.
In some embodiments, a weight ratio of the black tea ferment to the bioactive substance is 9:1 to 1:9.
In some embodiments, the prebiotic composition further includes erythritol, Arabic gum or a combination thereof.
In some embodiments, the prebiotic composition includes the black tea ferment, the bioactive substance and erythritol or Arabic gum; and a weight ratio of the black tea ferment to the bioactive substance to erythritol or Arabic gum is 1:1:0.05-2.
In some embodiments, the prebiotic composition includes the black tea ferment, the bioactive substance and erythritol; and a weight ratio of the black tea ferment to the bioactive substance to erythritol is 1:1:0.6-2.
In some embodiments, the prebiotic composition includes the black tea ferment, the bioactive substance and the Arabic gum; and a weight ratio of the black tea ferment to the bioactive substance to Arabic gum is 1:1:0.05-0.2.
In some embodiments, the prebiotic composition includes the black tea ferment, the bioactive substance, erythritol and Arabic gum; and a weight ratio of the black tea ferment to the bioactive substance to erythritol to Arabic gum is 1:1:0.6-2:0.05-0.2.
In some embodiments, the prebiotic composition includes the black tea ferment, the bioactive substance, erythritol and Arabic gum; and the weight ratio of the black tea ferment to the bioactive substance to erythritol to Arabic gum is 3:3:3.6:0.4.
In some embodiments, the bioactive substance is the soybean peptide powder.
In some embodiments, the prebiotic composition has an ability to promote the growth of Hafnia alvei.
In some embodiments, the prebiotic composition has an ability to increase the content of short-chain fatty acids (SCFAs) in intestinal tracts.
In some embodiments, the prebiotic composition has an ability to inhibit the appetite of the subject.
In some embodiments, the prebiotic composition has an ability to lose weight, and reduce body fat and waist circumference of the subject.
In some embodiments, the body fat is trunk body fat.
In some embodiments, the effective dose of the prebiotic composition is 500 g. In some embodiments, the prebiotic composition is administered twice a day.
In some embodiments, the composition for weight loss is in a capsule form and includes 500 g of the prebiotic composition.
In some embodiments, the composition for weight loss in the capsule form is administered twice a day.
In conclusion, the prebiotic composition according to any embodiment includes the black tea ferment and the bioactive substance, and has the abilities to promote Hafnia alvei, increase the content of the SCFAs in the intestinal tract, inhibit the appetite of the subject, lose the weight, and reduce the body fat (such as trunk body fat) and waist circumference of the subject. Moreover, the prebiotic composition can be used for preparing a composition for weight loss so as to help the subject to lose weight.
In the description of the following embodiments, unless otherwise specified, the symbol “%” refers to weight percentage, and the symbol “vol %” usually refers to volume percentage concentration.
A prebiotic composition includes a black tea ferment and a bioactive substance. The bioactive substance is a nitrogen-containing amino acid composition, such as peptide, oligopeptide, and protein. For example, the bioactive substance is soybean peptide powder, pea protein, rice protein, corn oligopeptide powder or a combination thereof. The black tea ferment is prepared by extracting tea leaves of Camellia sinensis with water and then fermenting with a plurality of strains.
In some embodiments, the soybean peptide powder, the pea protein, the rice protein and the corn oligopeptide powder are commercially available. For example, the soybean peptide powder can be purchased from FUJI OIL Co. Ltd., the pea protein can be purchased from Roquette, France, the rice protein can be purchased from Panel Japan Co. Ltd., Japan, and the corn oligopeptide powder is purchased from ZHONGSHIDUQING (SHANDONG) Biological Co. Ltd., China.
In some embodiment, the bioactive substance is preferably the soybean peptide powder.
In some embodiments, the black tea ferment is prepared by the following steps: mixing tea leaves of Camellia sinensis with water, and extracting at 50° C. to 100° C. for 0.5 hours to 3 hours to obtain a black tea extract; and then, fermenting the black tea extract which is cooled to reach room temperature for 12 days to 25 days by Saccharomyces cerevisiae BCRC20271 (International deposit number: ATCC26602), Bifidobacterium lactis BCRC910887 (International deposit number: DSM33303), Lactobacillus gasseri BCRC910886 (International deposit number: DSM33105) and Gluconacetobacter xylinus BCRC12335 to obtain the black tea ferment.
In some embodiments, the weight ratio of the tea leaves of the black tea to the water is 1:(50-125). For example, the weight ratio of the tea leaves to the water is 1:100.
In some embodiments, the black tea extract is subjected to extraction at a temperature of 90° C. for 1.2 hours. Moreover, sterilization can be performed while extraction.
In some embodiments, the inoculum size of Saccharomyces cerevisiae BCRC20271 is 0.01%-0.5% (v/v), the inoculum size of Bifidobacterium lactis BCRC910887 is 0.01%-0.25% (v/v), the inoculum size of Lactobacillus gasseri BCRC910886 is 0.01%-0.25% (v/v), and the inoculum size of Gluconacetobacter xylinus BCRC12335 is 10%-15% (v/v). For example, the inoculum size of Saccharomyces cerevisiae BCRC20271 is 0.15% (v/v), the inoculum size of Bifidobacterium lactis BCRC910887 is 0.03% (v/v), the inoculum size of Lactobacillus gasseri BCRC910886 is 0.035% (v/v), and the inoculum size of Gluconacetobacter xylinus BCRC12335 is 12% (v/v).
In some embodiments, the Saccharomyces cerevisiae BCRC20271, the Bifidobacterium lactis BCRC910887, the Lactobacillus gasseri BCRC910886 and the Gluconacetobacter xylinus BCRC12335 are simultaneously implanted into the black tea extract, and are totally fermented for 14 days.
For example, the Saccharomyces cerevisiae BCRC20271, the Bifidobacterium lactis BCRC910887, the Lactobacillus gasseri BCRC910886 and the Gluconacetobacter xylinus BCRC12335 can be strains purchased from Food Industry Research and Development Institute. In addition, the international deposit number of the Saccharomyces cerevisiae
BCRC20271 is ATCC26602, the international deposit number of the Bifidobacterium lactis BCRC910887 is DSM33303, the international deposit number of the Lactobacillus gasseri BCRC910886 is DSM33105, and the Gluconacetobacter xylinus BCRC12335 can be seen in a Taiwan Application with the application number as TW201819635A.
In some embodiments, steps for preparing the black tea ferment further includes: performing vacuum concentration at 45° C. to 70° C. after fermenting the black tea extract for 12 days to 25 days; adjusting Brix of the obtained product to 4.1±0.5°Bx (this is a condition for quality control and management); and then filtering by a sieve with 200-400 meshes to obtain the black tea ferment.
In some examples, the tea leaves of Camellia sinensis are mixed with water according to a weight ratio of 1:50-125, and extraction is carried out for 0.5 hours to 3 hours at the temperature of 50° C. to 100° C. to obtain the black tea extract. After the black tea extract is cooled to reach room temperature, 0.01%-0.5% (v/v) of Saccharomyces cerevisiae BCRC20271, 0.01%-0.25% (v/v) of Bifidobacterium lactis BCRC910887, 0.01%-0.25% (v/v) of Lactobacillus gasseri BCRC910886 and 10%-15% (v/v) of Gluconacetobacter xylinus BCRC12335 are synchronously inoculated to the cooled black tea extract and fermented. A primary black tea ferment solution is obtained after 12 days to 25 days. The primary black tea fermentation solution is subjected to vacuum concentration at 45° C. to 70° C., and the Brix is adjusted to be 4.1±0.5° Bx; and then filtering is carried out by the sieve with 200-400 meshes to obtain the black tea ferment.
In some embodiments, the prebiotic composition includes the black tea ferment and the bioactive substance in a weight ratio of 9:1 to 1:9. In some other preferred embodiments, the weight ratio of the black tea ferment to the bioactive substance is 4-7:6-3. In still some other preferred embodiments, the weight ratio of the black tea ferment to the bioactive substance is 1:1.
In some embodiments, the prebiotic composition further includes carbohydrate compounds and derivatives thereof. For example, the carbohydrate compounds and derivatives thereof include erythritol, arabinose, Arabic gum, fructooligosaccharide and the like. In some embodiments, the prebiotic composition further includes erythritol, Arabic gum or a combination thereof
For example, the prebiotic composition is a combination of the black tea ferment and the bioactive substance, a combination of the black tea ferment, the bioactive substance and erythritol, a combination of the black tea ferment, the bioactive substance and Arabic gum, and a combination of the black tea ferment, the bioactive substance, erythritol and Arabic gum.
In some embodiments, the prebiotic composition includes the black tea ferment, the bioactive substance and erythritol in a weight ratio of 1:1:1. In some other embodiments, the weight ratio of the black tea ferment to the bioactive substance to erythritol is 1:1:0.6-2.
In some embodiments, the prebiotic composition includes the black tea ferment,
the bioactive substance and Arabic gum in a weight ratio of 1:1:1. In some other embodiments, the weight ratio of the black tea ferment to the bioactive substance to Arabic gum is 1:1:(0.05-0.2).
In some embodiments, the prebiotic composition includes the black tea ferment, the bioactive substance, erythritol and Arabic gum in a weight ratio 1:1:0.6-2:0.05-0.2. In some other embodiments, the weight ratio of the black tea ferment to the bioactive substance to erythritol to Arabic gum is 1:1:1.2:0.1. In still some other embodiments, the weight ratio of the black tea ferment to the bioactive substance to erythritol to Arabic gum is 3:3:3.6:0.4.
Therefore, the black tea ferment obtained by a specific process can be mixed with the bioactive substance or the bioactive substance and the carbohydrate compounds in a specific proportion to obtain the prebiotic composition. The prebiotic composition can increase the quantity of specific probiotics in the intestinal tract of the subject by at least 7 folds.
In some embodiments, the prebiotic composition can improve the microflora of the intestinal tract. For example, the prebiotic composition can promote the growth of Hafnia alvei in the intestinal tract of the subject so as to increase caseinolytic peptidase B (C1pB protein) and short-chain fatty acids (SCFAs).
In some embodiments, the prebiotic composition can inhibit the appetite of the subject. For example, by taking the prebiotic composition, the satiety of the subject is increased, and the appetite can be inhibited, and thus excessive or excessive intake is reduced.
In some embodiments, the prebiotic composition can lose the weight, and reduce the body fat and waist circumference of the subject. For example, the body fat is trunk body fat.
Therefore, the prebiotic composition can be used for preparing a composition for weight loss.
In some embodiments, the composition for weight loss can be in a solid form, such as powder, a tablet and a capsule. For example, the composition for weight loss is in a capsule form, and contains 500 g of the prebiotic composition.
In some embodiments, the dosage of the prebiotic composition is 1,000 mg/d. For example, the prebiotic composition mainly includes the black tea ferment, the soybean peptide powder, erythritol and Arabic gum. 1,000 mg of the prebiotic composition per day means that the total amount of the black tea ferment, the soybean peptide powder, erythritol and Arabic gum is 1,000 mg.
In some embodiments, the composition for weight loss in the capsule form contains 500 g of the prebiotic composition, and is administrated twice per day.
Any one of the abovementioned prebiotic compositions can be a medicine. In other words, the medicine contains an effective content of the combination of the black tea ferment and the bioactive substance (such as the soybean peptide powder) in a specific proportion, or the combination of the black tea ferment, the bioactive substance (such as the soybean peptide powder), erythritol and/or Arabic gum.
In some embodiments, the aforementioned medicine can be made into dosage forms suitable for enteral, parenteral, oral, or topical administration using technologies well-known to those skilled in the art.
In some embodiments, the dosage forms suitable for enteral or oral administration can be, but are not limited to, the form of a tablet, a troche, a lozenge, a pill, a capsule, dispersible powder or granule, a solution, a suspension, an emulsion, syrup, an elixir, slurry or the like. In some embodiments, the dosage forms suitable for parenteral or topical administration can be, but are not limited to, the form of an injection, sterile powder, external preparation or the like. In some embodiments, the injection can be administrated by subcutaneous injection, intraepidermal injection, intradermal injection or intralesional injection.
In some embodiments, the medicine may include a pharmaceutically acceptable carrier which is widely applied to medicine manufacturing technologies. In some embodiments, the pharmaceutically acceptable carrier can be one or more of the following carriers: a solvent, a buffer, an emulsifier, a suspending agent, a decomposer, a disintegrating agent, a dispersing agent, a binding agent, an excipient, a stabilizing agent, a chelating agent, a diluent, a gelling agent, a preservative, a wetting agent, a lubricant, an absorption delaying agent, a liposome and the like. The types and quantity of the carriers to be the adopted are within the expertise and routine skill of those skilled in the art. In some embodiments, the pharmaceutically acceptable carrier may be water, normal saline, phosphate buffered saline (PBS), and aqueous solution containing alcohol.
In some embodiments, any of the abovementioned prebiotic compositions can be an edible product. In other words, the edible product includes a specific content of the combination of the black tea ferment and the bioactive substance (such as the soybean peptide powder) in a specific proportion, or the combination of the black tea ferment, the bioactive substance (such as the soybean peptide powder), erythritol and/or Arabic gum. In some embodiments, the edible product can be a general food, a healthcare food or a dietary supplement.
In some embodiments, the abovementioned edible product can be made into a dosage form suitable for oral administration using technologies well-known to those skilled in the art. In some embodiments, the abovementioned general food can be the edible product. In some embodiments, the general food can be, but is not limited to, beverages, fermented foods, baked products, or seasonings.
In some embodiments, the obtained prebiotic composition can be further used as a food additive to prepare a food composition containing the prebiotic composition prepared from the combination of the black tea ferment and the bioactive substance (such as the soybean peptide powder) in a specific proportion, or the combination of the black tea ferment, the bioactive substance (such as the soybean peptide powder), erythritol and/or Arabic gum in a specific proportion. Therefore, the prebiotic composition according to any embodiment can be added during raw material preparation by a known method, or the prebiotic composition according to any embodiment can be added in the food making process so as to be matched with any edible materials to prepare the edible product (namely the food composition) for human and non-human animals to eat.
Tea leaves of Camellia sinensis (purchased from TAIWAN TEA CORPORATION) was mixed with water according to a weight ratio of 1:100, and the obtained mixture was extracted at 90° C. for 1.2 hours to obtain a black tea extract. After the black tea extract was cooled to reach room temperature, 0.015% (v/v) of Saccharomyces cerevisiae BCRC20271, 0.03% (v/v) of Bifidobacterium lactis BCRC910887, 0.035% (v/v) of Lactobacillus gasseri BCRC910886 and 12% (v/v) of Gluconacetobacter xylinus BCRC12335 were synchronously inoculated to the cooled black tea extract, and fermented for 14 days to obtain a primary black tea fermentation solution. The primary black tea fermentation solution was subjected to vacuum concentration at 45° C. to 70° C., and the Brix was adjusted to be 4.1±0.5°Bx. Then filtering was carried out by a sieve with 200-400 meshes to obtain the black tea ferment.
The Saccharomyces cerevisiae BCRC20271, the Bifidobacterium lactis BCRC910887, the Lactobacillus gasseri BCRC910886 and the Gluconacetobacter xylinus BCRC12335 were strains purchased from Food Industry Research and Development Institute (FIRDI).
The single ingredient referred to 5 prebiotics (hereinafter referred to as a single-ingredient formula), including the black tea ferment prepared in Embodiment 1, soybean peptide powder (purchased from FUJI OIL Co. Ltd.), pea protein (purchased from Roquette, France), rice protein (purchased from Panel Japan Co. Ltd., Japan), and corn oligopeptide powder (purchased from ZHONGSHIDUQING (SHANDONG) Biological Co. Ltd., China), and there were five single-formula experimental groups from a single-formula experimental group A to a single-formula experimental group E. The complex ingredients referred to prebiotic compositions (hereinafter referred to as a complex-ingredient formula) formed by combinations of the black tea ferment prepared in Embodiment 1 and 4 bioactive substances (namely soybean peptide powder, pea protein, rice protein and corn oligopeptide powder), and there were 4 complex-formula experimental groups from a complex-formula experimental group a to a complex-formula experimental group d. An adopted liquid medium was a brain heart infusion broth (BHI, hereinafter referred to as a BHI medium, and purchased from Difco™). Adopted test strains were Hafnia alvei BCRC10906 purchased from Bioresource Collection and Research Center (BCRC).
The groups were divided into a control group, five single-formula experimental groups and four complex-formula experimental groups, as shown in Table 1.
Control group: No formula was added, and an experimental medium was 10 ml of the BHI medium.
Single-formula experimental group: A single-formula experimental group A containing the black tea ferment prepared in Embodiment 1, a single-formula experimental group B containing the soybean peptide powder, a single-formula experimental group C containing the pea protein, a single-formula experimental group D containing the rice protein and a single-formula experimental group E containing the corn oligopeptide powder. Moreover, the experimental medium of the single-formula experimental group A was 10 ml of the BHI medium containing 1 g of the black tea ferment prepared in Embodiment 1. The experimental medium of the single-formula experimental group B was 10 ml of the BHI medium containing 1 g of the soybean peptide powder. The experimental medium of the single-formula experimental group C was 10 ml of the BHI medium containing 1 g of the pea protein. The experimental medium of the single-formula experimental group D was 10 ml of the BHI medium containing 1 g of the rice protein. The experimental medium of the single-formula experimental group E was 10 ml of the BHI medium containing 1 g of the corn oligopeptide powder.
Complex-formula experimental group: A complex-formula experimental group a containing the black tea ferment prepared in Embodiment 1 and the soybean peptide powder, a complex-formula experimental group b containing the black tea ferment prepared in Embodiment 1 and the pea protein, a complex-formula experimental group c containing the black tea ferment prepared in Embodiment 1 and the rice protein, and a complex-formula experimental group d containing the black tea ferment prepared in Embodiment 1 and the corn oligopeptide powder. The experimental medium of the complex-formula experimental group a was 10 ml of the BHI medium containing 0.5 g of the black tea ferment prepared in Embodiment 1 and 0.5 g of the soybean peptide powder. The experimental medium of the complex-formula experimental group b was 10 ml of the BHI medium containing 0.5 g of the black tea ferment prepared in Embodiment 1 and 0.5 g of the pea protein. The experimental medium of the complex-formula experimental group c was 10 ml of the BHI medium containing 0.5 g of the black tea ferment prepared in Embodiment 1 and 0.5 g of the rice protein. The experimental medium of the complex-formula experimental group d was 10 ml of the BHI medium containing 0.5 g of the black tea ferment prepared in Embodiment 1 and 0.5 g of the corn oligopeptide powder.
Firstly, 5% (v/v) of Hafnia alvei was inoculated to the BHI medium, and activated in an anaerobic operation box (5% of hydrogen, 10% of carbon dioxide and 85% of nitrogen) at 37° C. for 24 hours to obtain an experimental bacterial solution.
5% (v/v) of activated Hafnia alvei was added into each of test tubes filled with 10 mL of the experimental medium of each group respectively, and subjected to anaerobic culture at 37° C. for 24 hours; and double repeated experiments were carried out. Then, after culturing for 24 hours, the bacterial solution of each group was shaken up. 200 μl of the bacterial solution was charged into to a 96-well plate. OD600nm of each group was detected within 15 minutes through a disc-type full-spectrum optical quantometer (Brand: BioTek; Model: EPOCH). The absorbance of the control group was regarded as the relative bacterial count of 100±3.81%, and the relative bacterial count (%) of other groups was correspondingly converted. The detection result and the converted relative bacterial count result are shown in
100 ± 3.81
As shown in
The groups were divided into a control group and 9 experimental groups. The adopted liquid medium was a brain heart infusion broth (BHI, hereinafter referred to as a BHI medium, and purchased from Difco™). The adopted test strains were Hafnia alvei BCRC10906 purchased from Bioresource Collection and Research Center (BCRC). Each group is shown as Table 3.
Control group: No prebiotics were added, and the experimental medium was 10 ml of the BHI medium.
9 Experimental groups: Experimental group [1] to experimental group [9] containing the black tea ferment prepared in Embodiment 1 and the soybean peptide powder in different proportions. The weight ratio of the prebiotic composition in the experimental groups was 1:9 to 9:1. The experimental medium of each group was 10 ml of the BHI medium containing 1 g of the prebiotic composition (namely, a combination of 0.1 g of the black tea ferment prepared in Embodiment 1 and 0.9 g of the soybean peptide powder, a combination of 0.2 g of the black tea ferment prepared in Embodiment 1 and about 0.8 g of the soybean peptide powder, a combination of 0.3 g of the black tea ferment prepared in Embodiment 1 and 0.7 g of the soybean peptide powder, a combination of 0.4 g of the black tea ferment prepared in Embodiment 1 and 0.6 g of the soybean peptide powder, a combination of 0.5 g of the black tea ferment prepared in Embodiment 1 and 0.5 g of the soybean peptide powder, a combination of 0.6 g of the black tea ferment prepared in Embodiment 1 and 0.4 g of the soybean peptide powder, a combination of 0.7 g of the black tea ferment prepared in Embodiment 1 and 0.3 g of the soybean peptide powder, a combination of 0.8 g of the black tea ferment prepared in Embodiment 1 and 0.2 g of the soybean peptide powder, and a combination of 0.9 g of the black tea ferment prepared in Embodiment 1 and 0.1 g of the soybean peptide powder). The 9 experimental groups are also referred to as formulas [1] to [9].
Firstly, 5% (v/v) of Hafnia alvei was inoculated to the BHI medium, and activated in an anaerobic operation box (5% of hydrogen, 10% of carbon dioxide and 85% of nitrogen) at 37° C. for 24 hours to obtain an experimental bacterial solution.
5% (v/v) of activated Hafnia alvei was added into each of test tubes filled with 10 mL of the experimental medium of each group respectively, and subjected to anaerobic culture at 37° C. for 24 hours; and double repeated experiments were carried out. Then, after culturing for 24 hours, the bacterial solution of each group was shaken up. 200 μl of the bacterial solution was charged into to a 96-well plate. OD600nm of each group was detected within 15 minutes through a disc-type full-spectrum optical quantometer (Brand: BioTek; Model: EPOCH). The absorbance of the control group was regarded as the relative bacterial count of 100±11.2%, and the relative bacterial count (%) of other groups was correspondingly converted. The detection result and the converted relative bacterial count result are shown in
As shown in
The groups were divided into a control group and 11 experimental groups. The experimental groups included 6 single-formula experimental groups and 5 complex-formula experimental groups, namely a single-formula experimental group [1] to a single-formula experimental group [6], and a complex-formula experimental group [1] to a complex-formula experimental group [5]. The adopted liquid medium was a brain heart infusion broth (BHI, hereinafter referred to as the BHI medium, and purchased from Difco™). The adopted test strains were Hafnia alvei BCRC10906 purchased from Bioresource Collection and Research Center (BCRC). Each group is shown as Table 5.
Control group: No prebiotics were added, and the experimental medium was 10 ml of the BHI medium.
6 single-formula experimental groups: A single-formula experimental group [1] containing erythritol (purchased from SWEET TOWN ENTERPRISE CORP.), a single-formula experimental group [2] containing arabinose (purchased from HIGHCHEM Co., Ltd.), a single-formula experimental group [3] containing Arabic gum (purchased from Buildmore Enterprise Co., Ltd.), a single-formula experimental group [4] containing fructooligosaccharide (purchased from Panel Japan Co., Ltd.), a single-formula experimental group [5] containing soybean peptide powder (purchased from FUJI OIL Co. Ltd.), and a single-formula experimental group [6] containing the black tea ferment prepared in Embodiment 1. The experimental medium of each group was 10 ml of the BHI medium containing 1 g of prebiotics (namely, erythritol, arabinose, Arabic gum, fructooligosaccharide, soybean peptide powder, the black tea ferment prepared in Embodiment 1. The 6 single-formula experimental groups were also called single-ingredient formulas [1] to [6]).
5 complex-formula experimental groups: A complex-formula experimental group [1] containing the black tea ferment prepared in Embodiment 1 and the soybean peptide powder; a complex-formula experimental group [2] containing the black tea ferment prepared in Embodiment 1, the soybean peptide powder and erythritol; a complex-formula experimental group [3] containing the black tea ferment prepared in Embodiment 1, the soybean peptide powder and fructooligosaccharide ; a complex-formula experimental group [4] containing the black tea ferment prepared in Embodiment 1, the soybean peptide powder and arabinose; and a complex-formula experimental group [5] containing the black tea ferment prepared in Embodiment 1, the soybean peptide powder and Arabic gum. The weight ratio of the prebiotic compositions of the complex-formula experimental groups was 1:1 or 1:1:1. The experimental medium of each group was 10 ml of the BHI medium containing 1 g of prebiotic composition (namely, a combination of 0.5 g of the black tea ferment prepared in Embodiment 1 and 0.5 g of the soybean peptide powder, a combination of about 0.33 g of the black tea ferment prepared in Embodiment 1, about 0.33 g of the soybean peptide powder and about 0.33 g of erythritol, a combination of about 0.33 g of the black tea ferment prepared in Embodiment 1, about 0.33 g of the soybean peptide powder and about 0.33 g of fructooligosaccharide , a combination of about 0.33 g of the black tea ferment prepared in Embodiment 1, about 0.33 g of the soybean peptide powder and about 0.33 g of arabinose, and a combination of about 0.33 g of the black tea ferment prepared in Embodiment 1, about 0.33 g of the soybean peptide powder and about 0.33 g of Arabic gum; and the 5 complex-formula experimental groups are also referred to as complex-ingredient formulas [1] to [5]).
Firstly, 5% (v/v) of Hafnia alvei was inoculated to the BHI medium, and activated in an anaerobic operation box (5% of hydrogen, 10% of carbon dioxide and 85% of nitrogen) at 37° C. for 24 hours to obtain an experimental bacterial solution.
5% (v/v) of activated Hafnia alvei was added into each of test tubes filled with 10 mL of the experimental medium of each group respectively, and subjected to anaerobic culture at 37° C. for 24 hours; and double repeated experiments were carried out. Then, after culturing for 24 hours, the bacterial solution of each group was shaken up. 200 μl of the bacterial solution was charged into to a 96-well plate. OD600nm of each group was detected within 15 minutes through a disc-type full-spectrum optical quantometer (Brand: BioTek; Model: EPOCH). The absorbance of the control group was regarded as the relative bacterial count of 100±3.81%, and the relative bacterial count (%) of other groups was correspondingly converted. The detection result and the converted relative bacterial count result are shown in
As shown in
Therefore, the prebiotic composition in certain proportion and specific variety could effectively and remarkably improve the growth ability of probiotics (like Hafnia alvei).
Herein, the specific prebiotic composition was obtained by combining the black tea ferment prepared in Embodiment 1, the soybean peptide powder (purchased from FUJI OIL Co. Ltd.), erythritol (purchased from SWEET TOWN ENTERPRISE CORP.) and Arabic gum (purchased from Buildmore Enterprise Co., Ltd.). The adopted liquid medium was the brain heart infusion broth (BHI, hereinafter referred to as the BHI medium, and purchased from Difco™). The adopted test strains were Hafnia alvei BCRC10906 purchased from Bioresource Collection and Research Center (BCRC). Each group is shown as Table 7.
The groups were divided into a control group and 3 experimental groups. The control group referred to a group without any prebiotics, and the experimental medium was 10 ml of the BHI medium. The experimental groups were an experimental group [1] to an experimental group [3] containing the black tea ferment prepared in Embodiment 1, the soybean peptide powder, erythritol and Arabic gum in different proportions. The experimental medium was 10 ml of the BHI medium containing 1 g of the prebiotic composition (namely a combination of about 0.38 g of the black tea ferment prepared in Embodiment 1, about 0.38 g of the soybean peptide powder, about 0.23 g of erythritol and about 0.02 g of Arabic gum, a combination of about 0.24 g of the black tea ferment prepared in Embodiment 1, about 0.24 g of the soybean peptide powder, about 0.48 g of erythritol and about 0.05 g of Arabic gum, and a combination of about 0.30 g of the black tea ferment prepared in Embodiment 1, about 0.30 g of the soybean peptide powder, about 0.36 g of erythritol and about 0.03 g of Arabic gum; and the 3 experimental groups are referred to as formulas [1] to [3]).
Firstly, 5% (v/v) of Hafnia alvei was inoculated to the BHI medium, and activated in an anaerobic operation box (5% of hydrogen, 10% of carbon dioxide and 85% of nitrogen) at 37° C. for 24 hours to obtain an experimental bacterial solution.
5% (v/v) of activated Hafnia alvei was added into each of test tubes filled with 10 mL of the experimental medium of each group respectively, and subjected to anaerobic culture at 37° C. for 24 hours; and double repeated experiments were carried out. Then, after culturing for 24 hours, the bacterial solution of each group was shaken up. 200 μl of the bacterial solution was charged into to a 96-well plate. OD600nm of each group was detected within 15 minutes through a disc-type full-spectrum optical quantometer (Brand: BioTek; Model: EPOCH). The absorbance of the control group was regarded as the relative bacterial count of 100±9.7%, and the relative bacterial count (%) of other groups was correspondingly converted. The detection result and the converted relative bacterial count result are shown in
As shown in
The composing proportion of the prebiotic composition in Embodiment 5-1 was further adjusted. The specific proportion referred to that the prebiotic composition was obtained by combining the black tea ferment prepared in Embodiment 1, the soybean peptide powder (purchased from FUJI OIL Co. Ltd.), erythritol (purchased from SWEET TOWN ENTERPRISE CORP.) and Arabic gum (purchased from Buildmore Enterprise Co., Ltd.) according to a weight ratio of 3:3:3.6: 0.4. The adopted liquid medium was the brain heart infusion broth (BHI, hereinafter referred to as the BHI medium, and purchased from Difco™) The adopted test strains were Hafnia alvei BCRC10906 purchased from Bioresource Collection and Research Center (BCRC).
The groups were divided into a control group and an experimental group. The control group referred to a group without any prebiotics, and the experimental medium of the control group was 10 ml of the BHI medium. The experimental group referred to a group of a specific prebiotic composition, and the experimental medium of the experimental group was the BHI medium containing 10% (w/v) of the specific prebiotic composition (equivalent to that 10 ml of the BHI medium contained 1 g of the specific prebiotic composition). The specific prebiotic composition included 0.3 g of the black tea ferment prepared in Embodiment 1, 0.3 g of the soybean peptide powder, 0.36 g of erythritol and 0.04 g of Arabic gum.
5% (v/v) of Hafnia alvei was inoculated to the BHI medium, and activated in an anaerobic operation box (5% of hydrogen, 10% of carbon dioxide, and 85% of nitrogen) at 37° C. for 24 hours to obtain an experimental bacterial solution.
5% (v/v) of the activated Hafnia alvei was respectively inoculated to the experimental mediums of certain groups and subjected to anaerobic culture at 37° C. for 24 hours; and moreover, double repeated experiments were carried out.
After culturing for 24 hours, the bacterial solution was shaken up. 200 μl of the bacterial solution was charged into to a 96-well plate. OD600nm of each group was detected within 15 minutes through a disc-type full-spectrum optical quantometer (Brand: BioTek; Model: EPOCH).
As shown in
The experiment was conducted to further confirm the influence of the specific prebiotic composition on a human body. The prebiotic composition obtained by combining the black tea ferment prepared in Embodiment 1, the soybean peptide powder (purchased from FUJI OIL Co. Ltd.), erythritol (purchased from SWEET TOWN ENTERPRISE CORP.) and Arabic gum (purchased from Buildmore Enterprise Co., Ltd.) in a weight ratio of 3:3:3.6:0.4 was tested.
Capsules, each containing 500 mg of the prebiotic composition, were provided for 10 subjects. Each person took 1 capsule (2 capsules per day) before breakfast and dinner every day for 4 consecutive weeks. In other words, the daily dosage of the prebiotic composition for each person was 1,000 mg. Moreover, fecal sampling, questionnaire feedback, and body composition measurement were performed at the 0th week (before administration) and the 4th week (after administration).
The 10 subjects were males or females aged from 20 to 55 who were consciously uncontrollable in appetite or have body fat of more than 25%.
The fecal sampling was to collect feces of the subjects, and the feces were delivered to an outsourcing detection unit (BIOTOOLS) to measure NGS microflora of the subjects and analyze the content of the short-chain fatty acids (SCFAs) in the intestinal tracts of the subjects. The strain for current NGS microflora detection was Hafnia alvei.
The questionnaire feedback was to analyze the questionnaire result after investigating through an international approved Council on Nutrition Appetite Questionnaire (CNAQ). The body composition measurement included body weight, body fat rate, waist circumference, and the like.
10 subjects were subjected to fecal sampling before taking the capsules containing the prebiotic composition (i.e., the 0th week) and after taking the capsules containing the prebiotic composition (i.e., the 4th week) respectively, and BIOTOOLS was commissioned to perform NGS microflora analysis, with the result shown in
Herein, the detected strain was Hafnia alvei.
As shown in
5 subjects were subjected to fecal sampling before taking the capsules containing the prebiotic composition (i.e., the 0th week) and after taking the capsules containing the prebiotic composition (i.e., the 4 th week) respectively, and BIOTOOLS was commissioned to perform analysis on the content of short-chain fatty acids (SCFAs) in the intestinal tracts, with the result shown in
As shown in
The appetite of the 10 subjects was investigated with the CNAQ before taking the capsules containing the prebiotic composition (i.e., the 0th week) and after taking the capsules containing the prebiotic composition (i.e., the 4th week). Moreover, the questionnaire feedback results of the 10 subjects are shown in
As shown in
The body composition of the 10 subjects was measured by a body fat meter (Brand: TANITA BC-601FS) and a tape measure before taking the capsules containing the prebiotic composition (i.e., the 0th week) and after taking the capsules containing the prebiotic composition (i.e., the 4th week) respectively. In addition, the body composition results of the subjects are shown in
Herein, the analyzed body composition items included body weight, body fat rate and waist circumference.
As shown in
As shown in
As shown in
In conclusion, the prebiotic composition containing the black tea ferment and the bioactive substance (such as the soybean peptide powder, the pea protein, the rice protein, the corn oligopeptide powder or the combination thereof) according to any embodiment of the present disclosure can be used for promoting the growth of Hafnia alvei, increasing the content of short-chain fatty acids in the intestinal tracts, inhibiting the appetite of the subjects, losing the weight of the subjects, reducing the body fat (such as trunk body fat) of the subjects and reducing the waist circumference of the subjects. Moreover, the prebiotic composition can be used for preparing the composition for weight loss and can also be used for controlling the appetite of the subjects.
Although the present disclosure has been described in considerable detail with reference to certain preferred embodiments thereof, the disclosure is not for limiting the scope of the invention. Persons having ordinary skill in the art may make various modifications and changes without departing from the scope and spirit of the disclosure. Therefore, the scope of the appended claims should not be limited to the description of the preferred embodiments described above.
This application claims the benefit of U.S. provisional application Ser. No. 63/359,204, filed on Jul. 8, 2022. The entirety of the above-mentioned patent application is hereby incorporated by reference herein and made a part of the specification.
| Number | Date | Country | |
|---|---|---|---|
| 63359204 | Jul 2022 | US |
